SIETES :: 92005 citas

Resultados de la búsqueda por CARDIOPATÍA ISQUÉMICA REFINAR BÚSQUEDA

1.

Anónimo. FDA rules Novo Nordisk’s diabetes drug reduces risk of heart attack, stroke, cardiovascular death. DIA Daily 2017:2. [Ref.ID 102035]

2.

Grosser T, Ricciotti E, Fitzgerald GA. The cardiovascular pharmacology of nonsteroidal anti-inflammatory drugs. Trends Pharmacol Sci 2017;38:733-48. [Ref.ID 101990]

3.

Dimmitt S, Stampfer H, Martin JH. When less is more – Efficacy with less toxicity at the ED50. Br J Clin Pharmacol 2017;83:1365-8. [Ref.ID 101984]

4.

Messerli FH, Bangalore S, Rimoldi S, Gasowski J, Nussberger J. Are ACE inhibitors acceptable ingredients in polypills?. Lancet 2017;390:26. [Ref.ID 101670]

5.

Li L, Geraghty OC, Mehta Z, Rotwell PM, on behalf of the Oxford Vascular Study. Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study. Lancet 2017;390:490-9. [Ref.ID 101638]

6.

Schoenfeld AJ, Redberg RF. The value of using registries to evaluate randomized clinical trial study populations. JAMA Intern Med 2017;177:889. [Ref.ID 101623]

7.

Maddox TM, Tang F, Downs JR, Masoudi FA, Virani SS, Daugherty SL, Rumsfeld JS. Applicability of the IMPROVE-IT trial to current patients with acute coronary syndrome: an NCDR research to practice project. JAMA Intern Med 2017;177:887-9. [Ref.ID 101622]

8.

Dondo TB, Hall M, West RM, Jemberg T, Lindahl B, Bueno H, Danchin N. ß-blockers and mortality after acute myocardial infarction in patients without heart failure or ventricular dysfunction. J Am Coll Cardiol 2017;69:2710-20. [Ref.ID 101613]

9.

Curfman G. Risks of statin therapy in older adults. JAMA Intern Med 2017;177:966. [Ref.ID 101591]

10.

Han BH, Sutin D, Williamson JD, Davis BR, Piller LB, Pervin H, Pressel SL, Blaum CS, for the ALLHAT Collaborative Research Group. Effect of statin treatment vs usual care on primary cardiovascular prevention among older adults. The ALLHAT-LLT randomized clinical trial. JAMA Intern Med 2017;177:955-65. [Ref.ID 101590]

11.

Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR, FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017;376:1713-22. [Ref.ID 101586]

12.

Bally M, Dendukuri N, Rich B, Nadeau L, Helin-Salmivaara A, Garbe E, Brophy JM. Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data. BMJ 2017;357:j1909. [Ref.ID 101568]

13.

Anónimo. Drugs for hypertension. The Medical Letter on Drug and Therapeutics Bulletin 2017;59:41-8. [Ref.ID 101527]

14.

Grosser T. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med 2017;376:1389-90. [Ref.ID 101526]

15.

Biffi A, Scotti L, Corrao G. Use of antidepressants and the risk of cardiovascular and cerebrovascular disease: a meta-analysis of observational studies. Eur J Clin Pharmacol 2017;73:487-97. [Ref.ID 101517]

16.

Prada-Ramallal G, Takkouche B, Figueiras A. Diverging conclusions from the same meta-analysis in drug safety: source of data (primary versus secondary) takes a toll. Drug Saf 2017;40:351-8. [Ref.ID 101501]

17.

Stolk LM, de Vries F, Ebbelaar C, de Boer A, Schalekamp T, Souverein P, ten Cate-Hoek A, Burden AM. Risk of myocardial infarction in patients with atrial fibrillation using vitamin K antagonists, aspirin or direct acting oral anticoagulants. Br J Clin Pharmacol 2017;83:agosto. [Ref.ID 101480]

18.

Yasmina A, de Boer A, Deneer VHM, Souverein PC, Klungel OH. Patterns of antiplatelet drug use after a first myocardial infarction during a 10-year period. Br J Clin Pharmacol 2017;83:632-41. [Ref.ID 101464]

19.

Flory J. Will cardiovascular outcomes data on newer diabetes drugs bury the older agents?. JAMA Intern Med 2017;177:301-2. [Ref.ID 101462]

20.

Nielsen PB, Skjøth F, Søgaard M, Kjældgaard JN, Lip GYH, Larsen TB. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ 2017;356:j510. [Ref.ID 101419]